337 related articles for article (PubMed ID: 34776933)
21. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.
Lewczuk P; Ermann N; Andreasson U; Schultheis C; Podhorna J; Spitzer P; Maler JM; Kornhuber J; Blennow K; Zetterberg H
Alzheimers Res Ther; 2018 Jul; 10(1):71. PubMed ID: 30055655
[TBL] [Abstract][Full Text] [Related]
22. Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers.
Novobilský R; Bartova P; Lichá K; Bar M; Stejskal D; Kusnierova P
Front Hum Neurosci; 2023; 17():1284416. PubMed ID: 38164192
[TBL] [Abstract][Full Text] [Related]
23. The Validation of Multifactor Model of Plasma Aβ
Jiao F; Yi F; Wang Y; Zhang S; Guo Y; Du W; Gao Y; Ren J; Zhang H; Liu L; Song H; Wang L
Front Aging Neurosci; 2020; 12():212. PubMed ID: 32792940
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.
Margraf NG; Jensen-Kondering U; Weiler C; Leypoldt F; Maetzler W; Philippen S; Bartsch T; Flüh C; Röcken C; Möller B; Royl G; Neumann A; Brüggemann N; Roeben B; Schulte C; Bender B; Berg D; Kuhlenbäumer G
Front Aging Neurosci; 2022; 14():783996. PubMed ID: 35237145
[TBL] [Abstract][Full Text] [Related]
25. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
Blennow K; Zetterberg H
Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
[TBL] [Abstract][Full Text] [Related]
26. Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population.
Gleerup HS; Sanna F; Høgh P; Simrén J; Blennow K; Zetterberg H; Hasselbalch SG; Ashton NJ; Simonsen AH
Front Aging Neurosci; 2021; 13():659898. PubMed ID: 34040512
[TBL] [Abstract][Full Text] [Related]
27. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
28. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
29. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.
Dhiman K; Gupta VB; Villemagne VL; Eratne D; Graham PL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Hone E; Blennow K; Zetterberg H; Martins RN
Alzheimers Dement (Amst); 2020; 12(1):e12005. PubMed ID: 32211500
[TBL] [Abstract][Full Text] [Related]
31. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease.
Manniche C; Simonsen AH; Hasselbalch SG; Andreasson U; Zetterberg H; Blennow K; Høgh P; Juhler M; Hejl AM
J Alzheimers Dis; 2020; 75(3):937-947. PubMed ID: 32390628
[TBL] [Abstract][Full Text] [Related]
34. An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform.
Li D; Mielke MM
Neurol Ther; 2019 Dec; 8(Suppl 2):73-82. PubMed ID: 31833025
[TBL] [Abstract][Full Text] [Related]
35. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
Frankfort SV; Tulner LR; van Campen JP; Verbeek MM; Jansen RW; Beijnen JH
Curr Clin Pharmacol; 2008 May; 3(2):123-31. PubMed ID: 18700307
[TBL] [Abstract][Full Text] [Related]
36. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
[TBL] [Abstract][Full Text] [Related]
37. Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer's disease.
Knudtzon SL; Nordengen K; Grøntvedt GR; Jarholm J; Eliassen IV; Selnes P; Pålhaugen L; Espenes J; Gísladóttir B; Waterloo K; Fladby T; Kirsebom BE
Neurobiol Aging; 2024 May; 141():74-84. PubMed ID: 38838442
[TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
[TBL] [Abstract][Full Text] [Related]
40. The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer's Disease.
Fan DY; Sun HL; Sun PY; Jian JM; Li WW; Shen YY; Zeng F; Wang YJ; Bu XL
Front Neurosci; 2020; 14():625844. PubMed ID: 33551734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
